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Regulated secretion of neuropeptides and neurotrophic factors critically modulates
function and plasticity of synapses and circuitries. It is believed that rising amyloid-β
(Aβ) concentrations, synaptic dysfunction and network disorganization underlie early
phases of Alzheimer’s disease (AD). Here, we analyze the impact of soluble Aβ1–42
assemblies on peptidergic secretion in cortical neurons and astrocytes. We show that
neurons and astrocytes differentially produce and release carboxypeptidase E (CPE)
and secretogranin III (SgIII), two dense-core vesicle (DCV) markers belonging to the
regulated secretory pathway. Importantly, Aβ1–42, but not scrambled Aβ1–42, dramatically
impairs basal and Ca2+-regulated secretions of endogenously produced CPE and SgIII
in cultured neurons and astrocytes. Additionally, KCl-evoked secretion of the DCV cargo
brain-derived neurotrophic factor (BDNF) is lowered by Aβ1–42 administration, whereas
glutamate release from synaptic vesicle (SVs) remains unchanged. In agreement with
cell culture results, Aβ1–42 effects on CPE and SgIII secretion are faithfully recapitulated
in acute adult brain slices. These results demonstrate that neuronal and astrocyte
secretion of DCV cargos is impaired by Aβ in vitro and in situ. Furthermore, Aβ-induced
dysregulated peptidergic transmission could have an important role in the pathogenesis
of AD and DCV cargos are possible candidates as cerebrospinal fluid (CSF) biomarkers.
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INTRODUCTION
Alzheimer’s disease (AD) is by far the most common cause of dementia in the elderly. The
characteristic clinical phenotype of AD is a gradual and progressive loss of memory and cognition
(Scheltens et al., 2016). Accumulation of abnormally folded amyloid-β (Aβ) peptides in extracellular
plaques and hyperphosphorylated tau proteins in intracellular tangles are two major pathological
hallmarks of AD. However, neuritic plaques and neurofibrillary tangles are only weakly correlated
with the degree of dementia in AD patients (Selkoe and Hardy, 2016). In contrast, decreased
synapse number is the major quantitative correlate of loss of memory and cognition in AD brain
(DeKosky and Scheff, 1990). Accordingly, a growing body of electrophysiological, biochemical
and behavioral evidence suggests that synaptic dysfunction and network disorganization centrally
underlie the progressive cognitive manifestations of the clinical AD occurring before the onset of
symptoms (Mucke and Selkoe, 2012; Palop and Mucke, 2016).
It has been shown that the concentration of soluble Aβ, but not insoluble Aβ deposits, is
a predictor of synaptic changes in AD and tracks the disease progression and cognitive decline
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(Lue et al., 1999; Koss et al., 2016). In fact, soluble Aβ species,
mainly Aβ1–42 oligomers, exert a pivotal role in the pathogenesis
of the synaptic damage at early stages of AD (Ferreira et al.,
2015; Viola and Klein, 2015; De Strooper and Karran, 2016).
Binding of Aβ to neuronal and glial plasma membranes causes
multiple aberrant effects that could trigger synaptic failure,
such as dysfunction of Ca2+ homeostasis, axonal transport,
neurotransmitter receptors and transporters and mitochondria.
Moreover, several studies have proposed that Aβ peptides can
affect synaptic function by altering vesicular release of classical
transmitters (i.e., glutamate) from neurons and astrocytes (Arias
et al., 1995; Abramov et al., 2009; Parodi et al., 2010; Brito-
Moreira et al., 2011; Talantova et al., 2013; Hascup and
Hascup, 2016). In this regard, two recent studies showing that
Aβ oligomers directly impair SNARE complex formation and
synaptic vesicle (SV) exocytosis further support a deleterious
function of aberrant Aβ on transmitter secretion (Russell et al.,
2012; Yang et al., 2015).
Besides SVs, the so-called dense-core vesicle (DCVs,
secretory granules in endocrine cells) store a wide array of
neuropeptides, hormones and growth factors that enable
peptidegic transmission. In neurons, and as recently proposed
astrocytes, DCVs-containing transmitters budding from trans-
Golgi network mature during transport along microtubules
toward the cell surface and secrete their cargos by Ca2+-
triggered exocytosis (Gondré-Lewis et al., 2012; Araque et al.,
2014). Although structure and function of synapses and networks
critically depend on the adjusted peptidergic transmission (van
den Pol, 2012), secretory features of DCVs in the normal and
pathological central nervous system have been little studied.
Here, we determined the impact of Aβ on secretion of DCV
cargos in cortical neurons and astrocytes. Therefore, we analyzed
in vitro and in situ release of carboxypeptidase E (CPE) and
secretogranin III (SgIII), two established DCVs markers which
are aberrantly accumulated in neurons and astrocytes in the
cerebral cortex of AD patients and amyloid-forming transgenic
mice (Plá et al., 2013). First, we show that neurons and astrocytes
produce distinctive forms of CPE and SgIII, which undergo
release via differential mechanisms. Importantly, basal and
regulated secretions of endogenously produced CPE and SgIII,
as well as brain-derived neurotrophic factor (BDNF), are
dramatically impaired by Aβ both in cultured dispersed cells
and acute brain slices. The present results indicate that DCVs
secretion is a significant target of amyloidogenic Aβ forms.
Moreover, a participation of Aβ-induced peptidergic secretion
alterations in the pathogenesis of AD and its potential use as a
cerebrospinal fluid (CSF) biomarker are suggested.
MATERIALS AND METHODS
Antibodies and Reagents
Monoclonal and polyclonal antibodies against CPE were
obtained from BD Transduction Laboratories (San Jose, CA,
USA) and GeneTex (Irvine, CA, USA). Polyclonal antibodies
against SgIII were purchased from Sigma-Aldrich (Madrid,
Spain). Aβ monoclonal antibodies, clones 4G8 and 6E10, were
from Covance (Emeryville, CA, USA). Polyclonal PC1/3 and
PC2 were from Thermo Fisher Scientific (Madrid, Spain) and
kindly provided by Dr I. Lindberg (University of Maryland),
respectively. Antibodies against GFAP, MAP-2, CD11b, Tuj1,
β-actin and Iba1 were from Millipore Iberica (Madrid, Spain),
Serotec (Oxford, UK), Sigma-Aldrich and Wako GmbH (Neuss,
Germany). DL-threo-β-benzyloxyaspartic acid (TBOA) was from
Tocris Bioscience (Bristol, UK). Most chemicals and cell culture
reagents were obtained from Sigma-Aldrich and Gibco (Thermo
Fisher Scientific), respectively.
Animals and Ethics Statement
CD1 mice were provided by Envigo Rms (Sant Feliu de Codines,
Spain), kept under controlled temperature (22 ± 2◦C), humidity
(40%–60%), and light (12-h cycles). All animals were handled
in accordance with the guidelines for animal research set out
in the European Community Directive 2010/63/EU, and all
procedures were approved by the Ethics Committee for Animal
Experimentation (CEEA), University of Barcelona (Barcelona,
Spain). All efforts were made to minimize the number used and
animal suffering.
Primary Cell Cultures and Acute Brain
Slices
Astroglial and neuronal cultures were obtained from CD1 mice
and prepared as described previously (Paco et al., 2009).
Astrocyte cultures were prepared from the whole cerebral cortex
of P0-P1-day-old mice. Cortical tissues were isolated, meninges
were carefully dissected away, minced and incubated in 0.5%
trypsin and 0.01% DNase. Dissociated cells were seeded in
flasks and grown in high-glucose Dulbecco’s Modified Eagle’s
Medium and F-12 (1:1) containing 10% fetal bovine serum,
10 mM HEPES and penicillin/streptomycin at 37◦C in a 5%
CO2 incubator. At confluence (10–12 days), flasks were shaken
overnight and the cells were rinsed, detached and subcultured
at 1 × 105 cells/cm2 onto poly-D-lysine-coated plastic culture
dishes and glass coverslips. Under these conditions, cell cultures
were essentially formed by astrocytes (>95% GFAP+), a small
percentage of microglia (<5% CD11b+) and virtually devoid
of neurons (<0.5% Tuj-1+). Neuronal cultures were grown
from either whole cerebral cortex (including hippocampus)
or isolated hippocampus of E16-E17 mouse embryos. After
trypsin and DNase treatment, dissociated cells were seeded at
1.5 × 105 cells/cm2 onto poly-D-lysine-coated culture plates
and glass coverslips. Neurons were grown in Neurobasal A
medium containing B27 and 1% FBS (Thermo Fisher Scientific),
glutamine and penicillin/streptomycin at 37◦C in a 5% CO2
atmosphere for 10 days. During the first 4 days, cultures were
also supplemented with 20µg/mL 5-Fluoro-2′-deoxyuridine and
50 µg/mL Uridine (Sigma-Aldrich) to inhibit mitotic activity of
glial cells. Tuj-1 and MAP2 immunostaining showed that more
than 95% of the cells were neurons, whereas a<5% were GFAP+
astrocytes.
Brain slices were obtained from anesthetized adult mice
(ketamine 120 µg/g and xylazine 6 µg/g i.p.), as described
previously (Aguado et al., 2002). Their brains were removed and
placed in cold artificial CSF (ACSF) containing (in mM): NaCl
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120, KCl 3, D-glucose 10, NaHCO3 26, NaH2PO4 2.25, CaCl2 2,
MgSO4 1, pH 7.4, bubbled with 95% O2 and 5% CO2. Horizontal
tissue slices (300 µm thick) were cut with a vibratome, stabilized
and transferred to a release chamber. All the experiments were
conducted in ACSF bubbled continuously with 95% O2 and 5%
CO2 at room temperature (22–25◦C).
Aβ Aggregation and Cell Viability
Synthetic human Amyloid-β1–42 (Aβ) peptide (H-1368), and
peptide comprised of the same amino acid composition of but
in a randomized sequence, Scrambled Amyloid-β1–42 (H-7406;
ScAβ), used as a control, were purchased from Bachem
(Bubendorf, Switzerland) and prepared as described previously
(Dahlgren et al., 2002). Lyophilized Aβ or ScAβ peptides
were initially dissolved to 1 mM in 1,1,1,3,3,3-Hexafluoro-
2-propanol (Sigma-Aldrich) and separated into aliquots in
sterile microcentrifuge tubes. Then, hexafluoroisopropanol was
evaporated under low temperature vacuum in a Speed Vac,
and the peptide film was stored desiccated at −80◦C until
use. For the assembly, the peptide was first resuspended
in anhydrous sterile dimethylsulfoxide (Sigma-Aldrich) to a
concentration of 5 mM, diluted to a final concentration of
100 µM in 10 mM HCl and incubated for 24 h at 37◦C.
Aggregated species in Aβ stocks were identified by western
blotting. Cultured cells and brain slices were treated with either
5 µM Aβ/ScAβ preparation or an equal volume of vehicle
solution (controls). Cell viability was determined by WST-1
(Roche, Basel, Switzerland), lactate dehydrogenase (Roche)
and propidium iodide/Hoechst (Sigma-Aldrich) assays. Levels
of reduced WST-1 and released lactate dehydrogenase were
measured with an ELISA plate reader (Tecan, Männedorf,
Switzerland) at 450 nm and 492 nm, respectively. Propidium
iodide/Hoechst uptake was analyzed by fluorescence microscopy
and analyzed with ImageJ software.
Release Assays
Secretion in cultured cells was assayed in 12-well culture plates
except for BDNF, for which it was done in 100 mm dishes
and for glutamate, for which 48-well plates were used. Poly-
D-lysine-attached cells were serum and supplement starved
prior to release experiments. Release assays in brain slices were
performed in superfused or static chambers (displaying the
same results). Secretion from cultured cells was performed in
commercial media and, when K+ and Ca2+ concentrations were
modified, in ACSF, whereas the release from brain slices was
always carried out in ACSF. The composition of the 55 mM
K+ ACSF was adjusted to maintain the osmolarity with a
corresponding NaCl decrease. In cultured cells, conditioned
media were collected and cells were washed in phosphate buffer
saline (PBS) and homogenized in lysis buffer (see below). Cell
media and superfusate and static ACSF from brain slices were
centrifuged at 600 g for 5 min to remove dislodged cells and all
samples were stored at −20◦C. Proteins in all release samples
were precipitated with 5% trichloroacetic acid, using sodium
deoxycholate as a carrier, or concentrated by Amiconr Ultra-15
and −0.5 Centrifugal filter devices (Merck Millipore, Madrid,
Spain).
CPE and SgIII were detected by western blotting (see
below) and Prep Cell Protein Standard was used as a control
for the precipitation protocol for conditioned media (Bio-Rad
Laboratories, Hercules, CA, USA). In cell culture media, β-actin
was used to normalize the secretion in order to minimize
variations in cell quantity. Levels of BDNF were quantified using
the BDNF EMAXr ImmunoAssay System according to the
manufacturer’s instructions (Promega Corporation, Madison,
WI, USA). Glutamate levels were measured using Amplex Red
Glutamic Acid/Glutamate Oxidase Assay kit (Molecular Probes,
Eugene, OR, USA) following the manufacturer’s protocol. BDNF
and glutamate levels were normalized by total protein levels.
Western Blotting
Cultured cells and tissues were homogenized in ice-cold lysis
buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
5 mM MgCl2, 1 mM ethyleneglycol-bis(2-aminoethylether)-
N,N,N′,N′-tetra acetic acid (EGTA), 1% Triton X-100, and
protease inhibitor cocktail (Roche Diagnostics). Samples of
conditioned media and postnuclear lysates were electrophoresed
in 8%–12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE; Bio-Rad Laboratories) and then
transferred to PVDF membranes (Bio-Rad Laboratories).
The membranes were activated and blocked in a solution
containing 5% nonfat milk powder in tris-buffered saline
tween-20 (140 mM NaCl, 10 mM Tris-HCl, pH 7.4, and 0.1%
Tween 20; TBS-Tween) for 1 h at room temperature and then
incubated with primary antibodies in blocking buffer for 2 h
at room temperature or overnight at 4◦C. After several washes
in TBS-Tween solution, the membranes were incubated for 1 h
with horseradish peroxidase-conjugated secondary antibodies
(Bio-Rad Laboratories). Bound antibodies were visualized with
enhanced chemiluminescence reagents (Bio-Rad Laboratories).
Blot images were scanned and densitometric analyses were
performed using ImageJ software.
Immunocytochemistry
Cells grown on glass coverslips were washed in ice-cold PBS and
fixed with 4% paraformaldehyde in PB for 15 min. Animals were
perfused transcardially under deep ketamine/xylacine anesthesia
with 4% paraformaldehyde in 0.1 M PB, pH 7.4. The brains
were removed from skulls, postfixed for 4 h in the same fixative
solution, and cryoprotected overnight at 4◦C by immersion in
a 30% sucrose solution in 0.1 M PB. Forty-micrometer thick
frozen sections were obtained with a cryostat and collected
in PBS. Sections processed for the peroxidase method were
soaked for 30 min in PBS containing 10% methanol and 3%
H2O2 and subsequently washed in PBS. To suppress nonspecific
binding, cell cultures and brain sections were incubated in 10%
serum-PBS containing 0.1% Triton X-100, 0.2% glycine and 0.2%
gelatin for 1 h at room temperature. Incubations with primary
antibodies were carried out overnight at 4◦C in PBS containing
5% fetal bovine serum, 0.1% Triton X-100 and 0.2% gelatin.
Some histological sections were processed using the avidin-
biotin-peroxidase method (Vectastain ABC kit, VECTOR,
Burlingame, CA, USA). The peroxidase complex was visualized
by incubating the sections with 0.05% diaminobenzidine and
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0.01% H2O2 in PBS. Sections were mounted, dehydrated and
coverslipped in Eukitt. Cell cultures and some brain sections
were processed for immunofluorescence using secondary
fluorochrome-conjugated antibodies (Alexa Fluor 488 and
Alexa Fluor 568, Molecular Probes, Eugene, OR), and cell
nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI,
Molecular Probes, Eugene, OR, USA). Cell-containing coverslips
and histological sections were mounted with Mowiol. The
specificity of the immunostaining was tested by omitting the
primary antibodies or by replacing them with an equivalent
concentration of nonspecific IgG. No immunostaining was
observed in these conditions. Bright field and fluorescent images
were obtained with the Olympus fluorescent BX-61 and Leica
TCS SPE scanning confocal microscopes.
Quantitative Real-Time PCR
RNA from cells was isolated by treatment with Trizolr reagent
(Invitrogen) following the manufacturer’s instructions and
the quantity and quality were determined with a NanoDrop
ND-1000 (NanoDrop Technologies, Wilmington, DE, USA) and
Bioanalyzer 2100 (Agilent, Waldbronn, Germany). cDNA was
synthesized using the Superscript III Reverse Transcriptase kit
(Invitrogen) from 1 µg of total RNA. Reactions were incubated
at 25◦C for 10 min, 50◦C for 30 min, 85◦C for 5 min, chilled
on ice and finally E. coli RNAse H was added and incubated
at 37◦C for 20 min. Quantitative real-time PCR (qPCR)
was performed using the StepOneTM Real-Time PCR System
(Applied Biosystems) using TaqMan Probes Mm00516341_m1
(CPE), Mm00485961_m1 (SgIII) and Mm01277042_m1 (TBP,
as housekeeping gene). The 20 µl PCR included 0.01 µl RT
product, 1× PerfeCTar qPCR FastMixr II with ROX (Quanta
BioSciences, Inc.) and 1 µL TaqMan probe. The reactions were
incubated in a 48-well plate at 95◦C for 5 min, followed by
42 cycles of 95◦C for 15 s, 58◦C for 15 s and 72◦C for 30 s.
All reactions were run in triplicate. The threshold cycle (CT) is
defined as the fractional cycle number at which the fluorescence
passes the fixed threshold.
Statistical Analysis
Data are shown as the mean ± Standard Error of the Mean
(SEM) summarizing three or more independent experiments,
performed at least in triplicates. Non-parametric one-way
ANOVA were calculated to determine significant effects
of treatments, using Kruskal-Wallis or Friedman test when
appropriate. Changes were calculated in relation to the average
of controls using Mann–Whitney or Wilcoxon tests as post hoc
analysis. Significance was set at ∗p < 0.05, ∗∗p < 0.01 and
∗∗∗p< 0.001.
RESULTS
Differential Mechanisms Underlie CPE and
SgIII Secretion from Neurons and
Astrocytes
First, we determined the in situ cellular location of the DCV
markers CPE and SgIII in the mouse cerebral cortex by
immunohistological methods. High levels of both proteins
were found in processes and cell bodies of pyramidal and
non-pyramidal neurons and astrocyte-like glial cells (Figure 1).
For neuronal CPE and SgIII, we detected differential location
patterns at the regional and subcellular levels. In general, CPE
immunostaining was more intense and more extended than for
SgIII (Figure 1). Both proteins were present in perikarya, but
only CPE was associated with dendritic shafts. Characteristically,
SgIII was found abundantly as immunoreactive puncta
throughout the neuropil, resembling axon terminals (Figure 1).
Differential location of these two DCV proteins in neurons
was apparent for the CA3 region of the hippocampus, where
CPE- and SgIII-labeled projections corresponded with dendrites
and mossy fibers, respectively (Figure 1). Regarding glial cells,
most cortical astrocyte-like somata through the gray and white
matters copiously displayed both CPE and SgIII (Figure 1).
Double immunofluorescence showed that non-neuronal CPE
and SgIII were associated with virtually all GFAP+ astrocytes and
absent in Iba1+ microglial cells (data not shown), in agreement
with our previous report (Paco et al., 2010).
To study peptidergic secretion from astrocytes and neurons,
we prepared cortical primary cultures highly enriched in each cell
type. Astrocyte cultures were virtually devoid of neurons, while
a small number of astrocytes (<5%) was present in neuronal
cultures which improved survival. In cultured astrocytes, CPE
and SgIII were associated with secretory organelles showing a
non-overlapping location, mainly for distal vesicles (Figure 2A).
CPE- and SgIII-immunolabeled vesicular compartments were
also evident in astrocytes grown within neuronal cultures
(Figure 2B). GFAP co-labeling was used to validate astroglial
identity. Careful analysis of media and cell lysates of glial
cultures by western blotting revealed that astrocyte CPE
and SgIII proteins corresponded to the nonprocessed forms
(∼55 kDa for CPE and ∼80–75 kDa for precursor SgIII, pSgIII;
Figure 2C). Because glial-produced proteins likely corresponded
to the uncleaved precursor forms, we determined whether
astrocytes lacked the corresponding PC1/3 and PC2 processing
prohormone convertases. Double immunocytochemical labeling
and Western blotting showed that in vitro astrocytes did not
express either PC1/3 or PC2 proteins (data not shown).
As previously reported for SgIII (Paco et al., 2010), we
show here that cultured astrocytes displayed high rates of basal
release of both CPE and SgIII (Figure 2C). To analyze secretory
kinetics of de novo synthesized CPE and SgIII in astrocytes,
extracellular and intracellular protein pools were analyzed during
cycloheximide (CHX) chase. As expected for secretory proteins,
untreated cells showed rising extracellular levels and steady
intracellular pools of CPE and SgIII over time. When protein
synthesis was blocked by CHX, decreasing levels of intracellular
CPE and SgIII were coupled with an almost invariable secreted
pool (Figure 2C). These observations show that newly generated
DCVs-like in astrocytes are poorly retained and rapidly undergo
exocytosis, independently of stimuli. Next, we evaluated the
regulated secretion of glial CPE and SgIII triggering [Ca2+]i
elevation by ionophores. Noteworthy, exposure to 1 µM
ionomycin over 15 min gave variable responses from one culture
set to another. Compared to unstimulated cultures, released
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FIGURE 1 | Neurons and astrocytes abundantly express carboxypeptidase E (CPE) and SgIII proteins in the cerebral cortex in vivo. Upper boxes illustrate
immunoperoxidase staining for CPE and SgIII in panoramic (left) and CA1 region (right) views of the hippocampal formation. Both proteins display a remarkable area
specific and laminar distribution. Neuronal CPE is primarily found in dendritic shafts (filled arrowheads) and perikarya, where mossy fibers robustly exhibit SgIII.
Intense immunolabeling for SgIII and CPE is detected in astroglial cell bodies and processes (arrows). Bottom boxes show confocal images of CPE (green) and SgIII
(red) double immunofluorescences in the hippocampal CA3 region. Both proteins are mainly associated with different neuronal domains. CPE is largely located in
somatodendritic compartments and SgIII is mainly distributed in terminal-like buttons of mossy fibers. Intense SgIII and CPE immunofluorescences colocalize in the
same astrocyte processes (arrows). Nuclei are stained in blue. Arrows and arrow-heads point to astroglial cells and interneurons, respectively. Filled arrow-heads
outline dendrites and asterisk indicates blood vessels. Scale bars in µm: upper-left, 250; upper-right and bottom, 50. Abbreviations: CA, regions of the
hippocampus; DG, dentate gyrus; mf, mossy fibers; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum.
CPE was higher after ionophore administration (181.4 ± 29.8%
over basal; p = 0.03), while no statistically significant changes
were observed for SgIII during stimulation (146.1 ± 25.4% over
basal; p = 0.3). Moreover, CPE and SgIII intracellular levels
were decreased after treatment (Figure 2D). Finally, the addition
of 55 mM KCl to the media did not substantially change the
levels of CPE nor SgIII secreted from astrocytes (Figure 2D). We
conclude that cultured astrocytes robustly produce unprocessed
forms of CPE and SgIII and largely release them in a stimulus-
independent fashion.
In neuronal cultures, CPE and SgIII were associated
with secretory organelles of pyramidal- and stellate-shaped
neurons (Figure 3A). In agreement with the above in vivo
data, a preferential location in dendrites was observed for
CPE, whereas SgIII was mainly associated with axon-like
projections and terminals. Neuronal and dendritic identities
were confirmed by double immunolabeling with MAP2. In
contrast to glial cells, cultured neurons produce and release both
the precursor and mature forms of CPE (∼55 and 53 kDa)
and SgIII (∼75 and 55 kDa; pSgIII and mSgIII respectively;
Figure 3B). Moreover, as anticipated by the mature form
occurrence of CPE and SgIII, cultured neurons abundantly
displayed the DCV-associated convertases PC1/3 and PC2
(Figure 3A).
Opposite to astrocytes, cultured neurons showed a very
low basal and high stimulus-triggered secretion of CPE and
SgIII (Figures 3B–D). Therefore, forcing Ca2+ entry during
15 min by 1 µM ionomycin addition increased up to fivefold
secretion from neuronal cells (Figure 3D). Depolarization by
KCl for 15 min resulted in a dramatic enhancement of CPE
and SgIII release (Figure 3C). Although shorter stimulation
times, such as 5 min, offered similar results, 15 min of
depolarization was maintained to ensure detection of released
proteins by Western blotting. K+-evoked secretion of CPE
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FIGURE 2 | Localization and release of CPE and SgIII in cultured cortical astrocytes. (A,B). Confocal immunofluorecence images in astrocytes grown in glial (A) and
neuronal (B) enriched cultures. High magnification in (A) shows a poor co-localization (yellow signal) of CPE (green) and SgIII (red) around the nucleus (blue). The
astrocyte identity of a process-bearing cell positive for SgIII (red) is revealed by GFAP (green) co-staining (right in B). In (B), arrow-head points to a neuronal soma
displaying SgIII (red) and n indicates nucleus location. Scale bars in µm: (A) 5; (B) 15. (C) Immunoblots illustrate cellular content (lysates, L) and basal secretion into
the medium (M) of CPE and SgIII in astrocyte cultures treated or not with 7.5 µM CHX during 1.5 h, 3 h and 6 h. β-actin was used as loading control. The graphs
below summarize percent variation of the extracellular (lines) and intracellular (bars) levels of CPE and SgIII after CHX administration compared to controls. Data are
presented as the mean ± standard error of the mean (SEM) of a representative experiment performed in quadruplicates. (D) Histograms summarizing the effect of
1 µM ionomycin (Iono) and 55 mM KCl incubations over 15 min on release (M) and cell content (L) of CPE and SgIII. Values represent percent variation compared
with controls and are presented as the mean ± SEM. All the data (M and L) was normalized by intracellular levels of β-actin. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001,
Mann-Whitney test.
was enhanced by a 279% over basal, whereas a 289% was
observed for SgIII forms. Because nominally Ca2+-free medium
virtually abolished DCVs release, K+-induced release of CPE
and SgIII in cultured neurons entirely depended on the influx
of this cation (Figure 3C). Interestingly, Ca2+-evoked SgIII
secretion was stronger for mature forms than for precursors
in both ionomycin (1.7 m/p ratio) and KCl (2.0 m/p ratio)
stimulations. These data indicate that neuronal and astroglial
DCVs undergo differential proteolytic processing and exocytotic
profiles.
Aβ Alters Production and Release of CPE
and SgIII in Cultured Astrocytes
To determine whether Aβ alters glial and neuronal DCVs
secretion, we prepared Aβ assemblies incubating Aβ1–42 peptides
for 24 h at 37◦C. Immunoblotting with 6E10 and 4G8 Aβ
antibodies revealed that Aβ preparations contained a broad
mixture of low- (20–50 kDa) and high-molecular-weight
(>50 kDa) aggregates, as well as the Aβ monomers, trimers and
tetramers (Figure 4). Consistent with previous reports (Moreth
et al., 2013), mono-tetrameric species were instantaneously
formed, whereas larger oligomeric aggregates appeared over
time of aging. No immunoreactive bands were detected from
∼200 kDa to the top/entrance of the gels (Figure 4).
Cell viability of cultured cells incubated with 5 µM
Aβ was evaluated at 24 h for astrocytes and 16 h for
neurons. Cellular membrane integrity was analyzed by a
propidium iodide/Hoechst uptake test. No changes were
observed between Aβ-treated and untreated cell cultures (Aβ vs.
control: 99.6 ± 0.7%, p = 0.8 for neurons and 100.2 ± 0.8%,
p = 0.9 for astrocytes). Due to the vulnerability of neurons,
2 additional tests were performed. WST-1 reduction was
evaluated to detect variations in the mitochondrial metabolic
rate, finding no significant changes (111.7± 4.7% of the control,
p = 0.14). Additionally, the release of the cytoplasmic enzyme
lactate dehydrogenase was analyzed in neuronal supernatant,
showing no increase in response to Aβ (97.7 ± 3.6% of
the control, p = 0.6). Because no differences were found
between Aβ- and vehicle-treated cultures in any of the tests
performed, no toxicity was found at the incubation times
used.
Next, we analyzed the effect of Aβ on astrocyte CPE and SgIII
secretion. Because the weak regulated release of these proteins
in glia, we focused on their basal secretion at 8 and 24 h.
Incubation of astrocytes with 5 µM Aβ caused a significant
reduction in the extracellular levels of SgIII and CPE, mainly
at 8 h (65% for SgIII and 41% for CPE) compared with
controls (vehicle-treated cells; Figures 5A,B). The unchanged
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FIGURE 3 | Cellular distribution and release of CPE and SgIII in cultured neurons of the cerebral cortex. (A) Confocal immunofluorescence shows a prominent
dendritic location for CPE (green) in pyramidal- and stellate-shaped neurons, while SgIII (red, left) is found in cell bodies and axon-like processes. No apparent
colocalization was observed for the 2 proteins. Abundant signal shows the presence of the PC1/3 (red, inset) and PC2 (red, right) in the cultured neurons, with a
broad somatic distribution. Scale bar in µm: 10. (B) Western blots show a very low basal secretion for CPE and SgIII, which were abundantly released in response to
depolarization by KCl 55 mM for 15 min. Both forms of SgIII (arrow: proform, p and arrowhead: mature, m) were found in the extracellular media (M). No changes
were found at intracellular levels in the lysate fraction (L). β-actin was used as loading control. (C) Release in response to KCl-depolarization was significant for CPE
and both p- and mSgIII, the latter being especially high. In all cases, evoked secretion was abolished in absence of Ca2+, showing a Ca2+ dependance. (D) 1 µM
Ionomycin was used to trigger the CPE and SgIII release. Graphs show the percent variation compared with controls and are presented as the mean ± SEM
normalized by intracellular levels of β-actin. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, Mann-Whitney test.
CPE and SgIII levels in culture media of astrocytes incubated
with a scrambled amino acid sequence of Aβ1–42 (5 µM
ScAβ) substantiated the specific effect of the aberrant amyloid
on released glial proteins. To assess whether decreased levels
into the media correlated with a diminished production or
an impaired release, intracellular SgIII and CPE levels were
assayed in Aβ- and ScAβ-treated cells. Concomitantly with a
reduction in secreted CPE and SgIII, Aβ markedly increased
their cellular content, mainly for SgIII (320% at 8 h and
257% at 24 h, p < 0.0001). No differences were detected after
incubation with ScAβ peptides (Figures 5A,B). In addition to an
impaired secretion, an Aβ-induced transcriptional dysregulation
could contribute to change extra- and intracellular levels of
secretory proteins. Therefore, we performed qPCR analysis for
CPE and SgIII mRNA in Aβ-treated and control astrocytes.
We found that levels of CPE transcripts were upregulated
by amyloid species (158.1 ± 18.7% of control, p = 0.03),
whereas SgIII mRNA expression was declined (70.2 ± 7.8%
of control, p = 0.004; Figure 5C). Taking together, these
results indicate that Aβ differentially regulates CPE and SgIII
transcription and consistently impairs their protein secretion in
astrocytes.
Regulated Secretion of DCV Cargos from
Cultured Neurons is Impaired by Aβ
To evaluate the impact of Aβ on neuronal DCV release, primary
cultures were exposed to vehicle (control) and 5 µM Aβ
and ScAβ preparations for 16 h, then basal and K+-evoked
release were analyzed by immunoblotting. A representative
experiment in Figure 6A illustrates no differences in the
intracellular levels of CPE, SgIII forms and β-actin after
Aβ-treatments (data quantification not shown). However, a
significant decrease of basal secretion was detected for CPE
(73% of control, p < 0.0001) and precursor (75% of control,
p = 0.007) and mature (66% of control, p = 0.0005) SgIII
forms in Aβ-exposed neurons, but not in cells incubated with
ScAβ (Figures 6A,B). Importantly, Aβ specifically impaired K+-
depolarized release of CPE (Aβ 203.3% vs. control 363.2%,
p < 0.0001), pSgIII (Aβ 190.0% vs. control 302.1%, p = 0.006)
and mSgIII (Aβ 245.3% vs. control 426.0%, p < 0.0001) but
not ScAβ (Figures 5A,B). Furthermore, an immunocytochemical
analysis was performed on MAP2-identified neurons to examine
subcellular distribution. Comparing neurons exposed to amyloid
with vehicle (control), aberrant immunoreactive accumulations
around the nuclei were detected in Aβ-treated cultures. This
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 June 2017 | Volume 10 | Article 202
Plá et al. Amyloid-β Impairs Peptidergic Secretion
FIGURE 4 | Characterization of aggregates present in the Aβ preparations.
Immunoblots illustrate 6E10- and 4G8-immunoreactive soluble Aβ1–42 peptide
before and after 24 h incubation at 37◦C. Monomeric (1-mer), trimeric (3-mer)
and tetrameric (4-mer) forms of Aβ are detected in both preparations, whilst
low molecular weight (lmw) and high molecular weight (hmw) aggregates are
only detected after the 24 h-incubation.
abnormal distribution was mainly associated with pyramidal-
shaped cells and principally occurred for SgIII (Figure 6C).
The present observations evidence that Aβ strongly alters the
regulated secretory pathway in neurons, impairing the evoked
release of CPE and SgIII.
Probably, the most studied DCV protein in brain-related
diseases is the pleiotrophic growth factor BDNF (Adachi
et al., 2014). With the aim to analyze whether release of
physiologically relevant DCV cargos is affected by Aβ, we
investigated secretion of endogenously produced BDNF by a
sensitive sandwich immunoassay. First, we assessed BDNF levels
in the same cortical-derived neuronal cultures used for CPE and
SgIII analysis. However, cellular content of BDNF in cultured
whole cortices was very low (8.6 ± 2.7 pg per 5×106 cells).
Therefore, although K+-evoked secretion could be determined,
basal secretion was under detectable levels. In order to achieve
detectable basal levels, we prepared BDNF-enriched cultures by
isolating hippocampal neurons (Chen et al., 2006). Intracellular
BDNF in hippocampal neurons was around four-fold higher than
in whole cortical cultures (38.8 ± 4.9 pg per 5×106 cells). No
significant differences were found in intracellular BDNF levels in
untreated and 5 µM Aβ treated cells for 16 h (control 0.61 vs.
Aβ 0.53 pg BDNF/µg protein, p = 0.6). As shown in Figure 7,
depolarization-stimulated secretion of BDNF in hippocampal
neurons was greatly impaired by Aβ exposure (Aβ 439.6% vs.
control 1055.0%, p = 0.003), whereas basal release levels were
unchanged (94.8% of control, p= 0.5). Furthermore, immunoblot
examination of CPE and SgIII secretion patterns in Aβ-treated
hippocampal neurons offered similar results to those obtained
in whole cortical cultures. Decrease in basal secretion was 44%
for CPE (p = 0.0002), 23% for pSgIII (p = 0.003) and 53% for
mSgIII (p = 0.01) in Aβ-treated hippocampal cultures, whereas
K+-depolarized release was impaired by a 64.7% (p = 0.007),
FIGURE 5 | Basal release and production of CPE and SgIII is altered in Aβ-treated cultured astrocytes. (A) Western blots showed basal release from cortical
astrocytes treated with 5 µM Aβ during 8 or 24 h. A marked reduction in the extracellular levels (media, M) of SgIII and CPE compared with controls and an
intracellular (lysates, L) accumulation is found in response to treatment with Aβ. No changes were found in response to ScAβ, either in the extracellular medium or the
content. β-actin was used as loading control. (B) Graphical representation of the levels of CPE and SgIII compared with the vehicle-treated levels. Data are presented
as the β-actin-normalized mean ± SEM. (C) mRNA quantification by Quantitative Real-Time PCR (qPCR) of CPE and SgIII of Aβ-treated cells (16 h) compared with
the vehicle-treated levels. Values represent percent variation compared with controls and are presented as the mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001,
Mann-Whitney test.
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FIGURE 6 | Aβ impairs regulated secretion of CPE and SgIII in cultured cortical neurons. (A) Western Blot analysis shows a decrease in the release of CPE and SgIII
both in basal and stimulated conditions in response to β-amyloid compared with vehicle-treated controls. Intracellular levels were unaffected by the treatment. β-actin
was used as loading control. (B) Summary of Aβ and ScAβ effects on basal and evoked secretion of CPE, pSgIII and mSgIII. Data are presented as the
β-actin-normalized mean ± SEM. ∗∗p < 0.01; ∗∗∗p < 0.001, Mann-Whitney test. (C) Confocal immunofluorescent images show an aberrant intracellular
accumulation of SgIII in Aβ-treated neurons, mainly localized around the nucleus. Scale bar in µm: 10.
FIGURE 7 | Aβ effects on brain-derived neurotrophic factor (BDNF) and
glutamate release in hippocampal cultured neurons. (A) Intracellular BDNF
content (lysates, L) in neuronal cultures was no affected by 5 µM Aβ during
16 h, whereas K+-stimulated release was decreased (media, M). (B)
Extracellular glutamate levels were decreased in basal media of neurons
treated with 5 µM Aβ during 16 h, whereas no changes were observed after
KCl stimulation. Inhibiting glutamate re-uptake by TBOA shows that released
neurotransmitter was unchanged during depolarization but decreased at basal
conditions. Values were normalized by total proteins levels and represent
percent variation compared with controls and are presented as the
mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, Wilcoxon test.
50.9% (p = 0.01) and 43.4% (p = 0.03) for CPE, pSgIII andmSgIII,
respectively.
Finally, to compare Aβ effects on neuronal DCV secretion
with those on SV exocytosis, we determined glutamate release
in hippocampal neurons exposed to 5 µM Aβ for 16 h by
a fluorometric assay. Compared to unstimulated conditions,
glutamate levels in the media were robustly increased during
K+-evoked depolarization (1176% over basal). Incubation of Aβ
caused a significant decrease in extracellular glutamate levels
at basal conditions (78.1% of control), whereas no changes
were observed during stimulation (Figure 7). To ascertain
the reliable contribution of secretion in extracellular glutamate
levels, its re-uptake was blocked by addition of the excitatory
amino acid transporter inhibitor TBOA (75 µM). In all
TBOA-treated samples, extracellular glutamate concentrations
were higher than in non-blocked conditions. Similar to the
results obtained without the transporter inhibitor, in absence
of glutamate re-uptake, Aβ reduces levels of glutamate released
in unstimulated cells (41.4% of control) but does not influence
secretion in KCl-depolarized neurons (Figure 7). Taken together,
these results show that Aβ specifically impairs Ca2+-regulated
secretion of DCVs in neuronal populations.
Aβ Impairs DCV Secretion in Adult Neural
Cells In Situ
To gain further insight into the impact of Aβ on regulated
secretory pathway in neural cells, we next performed experiments
on acute brain slices from adult mice. A major advantage of
slice preparations is that cells in situ largely retain the states
of differentiation, cytoarchitecture, extracellular matrix and
synaptic circuits of the intact adult brain. First, we characterized
CPE and SgIII secretion in horizontal adult brain slices under
different conditions by western blot analysis (Figure 8). Low
levels of both proteins were detected in unstimulated slices.
However, CPE and SgIII release markedly increased after 10 min
of a depolarizing stimulus (55 mM [K+]0). Cell integrity in the
slice was confirmed by the lack of vesicular integral and cytosolic
proteins, such as synaptophysin and actin, in the extracellular
media. As occurred in cultured neurons (Figure 3C), KCl-evoked
secretion of mSgIII form was stronger than for precursors
(Figure 8B). To determine the involvement of Ca2+ in the evoked
secretion of CPE and SgIII, we performed similar experiments in
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FIGURE 8 | Basal and depolarization-evoked release of CPE and SgIII from
adult acute brain slices. (A) Representative immunoblots detecting different
proteins in the perfused artificial CSF (ACSF) of the same slice after 15 min of
basal (−) and 55 mM KCl (+) conditions. β-actin and synaptophysin (Syp) were
used to confirm slice integrity and prestained proteins were added to ensure
correct sample concentration (precipitation control, pc). Forebrain
homogenates were used as input. (B) Histograms summarize variations of
released CPE, pSgIII and mSgIII after KCl stimulation in normal (2mM [Ca2+]0)
and nominally Ca2+-free (0 mM [Ca2+]0, 2 mM EGTA) ACSF compared with
basal conditions, showing mean ± SEM. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001, Mann-Whitney test.
a nominally Ca2+-free ACSF. Lack of extracellular Ca2+ totally
prevented the K+-induced CPE and SgIII secretion (Figure 8B).
These results show that in situ adult neural cells of the brain
release CPE and SgIII in a depolarization- and Ca2+-dependent
manner.
To compare DCV secretion in the same cell populations
between control and Aβ-treated brain slices, we split horizontal
brain slices into left and right hemispheres (Figure 9A),
minimizing the variability associated with cellular composition
and responsiveness inherent to each slice. Each pair of
hemispheres was incubated with vehicle (control) and 5 µM Aβ
or 5 µM ScAβ for 8 h and basal and K+-evoked secretion of
CPE and SgIII were analyzed by immunoblotting and statistical
analysis was performed using aWilcoxon test (Figures 9B,C). Aβ
notably reduced depolarization-evoked release of CPE (Aβ 334%
vs. control 475.9%, p = 0.0005), pSgIII (Aβ 232.9% vs. control
348.3%, p = 0.0068) and mSgIII (Aβ 299.1% vs. control 456.2%,
p = 0.0015). Moreover, basal secretion of CPE and mSgIII was
also impaired by Aβ (88.0% and 89.1% of controls, respectively).
No changes were observed in hemispheric slices incubated with
ScAβ (Figures 9B,C).
In summary, these results evidence that Aβ impairs DCV
secretion in cultured cortical cells and adult neural networks
in situ.
DISCUSSION
The major finding of this study is that aberrant Aβ markedly
impairs neuronal and astrocyte secretion of endogenously-
produced DCV cargos in vitro and in situ. CPE and SgIII
are two established DCV markers that belong to the regulated
secretory pathway of neurons and endocrine cells with
recognized roles in sorting, trafficking and processing of peptidic
cargos and proposed new functions as intercellular transmitters
(Bartolomucci et al., 2011; Cawley et al., 2012; Cheng et al., 2014).
Here we show that neurons and astrocytes produce specific
CPE and SgIII forms which are released in a cell type specific
manner. CPE, SgIII and BDNF secretion, but not glutamate
release, is dramatically impaired by Aβ in dispersed neurons and
astrocytes in culture. Furthermore, similar detrimental effects of
Aβ assemblies on basal and evoked release of DCV cargos are
observed on treated acute brain slices.
Secretion of DCV Cargos in Neurons and
Astrocytes
As well as their known expression by neurons, CPE and SgIII
are also abundantly produced by astrocytes in vitro and in vivo
(Paco et al., 2010). In agreement with a previous study performed
in human brains (Plá et al., 2013), we found a segregate
location of CPE and SgIII in DCV subsets in mouse neurons
and astrocytes. Irrespective whether neurons were analyzed in
cultures o in situ, a preferential somatodendritic location was
observed for CPE, whereas SgIII was mainly associated with
axons and terminal-like buttons. A non-overlapping vesicular
location of these proteins was also found in cultured astrocytes.
These observations lend support to the idea of differential routing
and release of DCV cargos in the same secretory cell (Fisher et al.,
1988; Zhang et al., 2011). Furthermore, the separate vesicular
distribution of CPE and SgIII noticed here may imply differences
in sorting mechanisms of neural cells compared with those
described in endocrine cells (Hosaka et al., 2005; Cawley et al.,
2016).
Although both CPE and SgIII are indeed expressed by
neurons and astrocytes, we found important differences in
the forms produced and their release dynamics comparing
cultures of each cell type. First, probably due to the lack of the
prototypical prohormone convertases of the regulated secretory
pathway (PC1/3 and PC2; Winsky-Sommerer et al., 2000),
astrocyte CPE and SgIII forms correspond to nonprocessed
precursors. Additionally, a differential secretory profile was
observed between neurons and astrocytes. Stimuli that evoked
robust CPE and SgIII release in neurons barely provoked a
response in astrocytes. In good agreement with a seminal work
analyzing secreted CPE enzymatic activity from Fricker’s lab
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 June 2017 | Volume 10 | Article 202
Plá et al. Amyloid-β Impairs Peptidergic Secretion
FIGURE 9 | Aβ impairs CPE and SgIII secretion in acute adult brain slices. (A) Left and right hemispheres of the same slice were incubated in parallel with vehicle and
Aβ or vehicle and ScAβ for 8 h. (B) Immunoblots showing released CPE and SgIII from representative paired hemispheres after 15 min of basal (−) and 55 mM KCl
(+) conditions. (C) Summary of Aβ and ScAβ effects on basal and evoked secretion of CPE, pSgIII and mSgIII. Values represent percent variation compared with
basal release of controls (mean ± SEM). Statistical significance: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, Wilcoxon test.
(Vilijn et al., 1989), we observed no response of released CPE
and SgIII to elevated [KCl]o from astrocytes. In addition,
increasing [Ca2+]i by ionophores caused variable and weak
release responses in glial cells. Furthermore, we show that
newly synthesized CPE and SgIII in non-stimulated astrocytes
are poorly retained and rapidly released. Taken together, these
observations would suggest that although bonafide CPE and
SgIII are produced in astrocytes, they are not sorted and
stored in typical DCVs. Based essentially on cell cultures, recent
studies have proposed the occurrence of DCVs in astrocytes
(Verkhratsky et al., 2016). However, several typical hallmarks
of neuronal and endocrine DCVs (e.g., size, core density, long
residence in cytoplasm, presence of synaptobrevin2, robust
stimulus-dependent exocytosis) have hardly been demonstrated
in cultured astrocytes (Crippa et al., 2006; Potokar et al.,
2008; Paco et al., 2009). Because astrocytes in vitro display
a partially immature phenotype and they do not accurately
reproduce their in vivo attributes, DCV features in astroglial
cells may be higher in situ than in culture. In fact, regulated
gliosecretion of DCV components in cultured cells is enhanced
under differentiating conditions, such as activation of the
cAMP pathway and tone attenuation of the REST/NRSF
transcription factor (Paco et al., 2009, 2016; Prada et al., 2011).
On this basis, the typical size and dense core characteristics
of neuroendocrine DCVs have been evidenced in granin-
containing vesicles of human astrocytes in vivo (Hur et al.,
2010).
Peptidergic Secretion as a New Target
for Aβ
Aβ dramatically impairs neuronal and astrocyte secretion of
DCV cargos in vitro and in situ. In unstimulated astrocyte
cultures Aβ exposure dramatically reduced levels of CPE
and SgIII released over 8–24 h. Conversely, intracellular
amounts were increased without an apparent correlation
with transcriptional mechanisms. Due to the poor cytoplasm
retention observed for exocytic vesicles, CPE and SgIII secretion
decrease and intracellular accumulation induced by Aβ in
astrocytes probably reflects an impairment of the secretory
pathway. In neuronal cultures, overnight incubation with Aβ
did not provoke apparent changes in intracellular levels of the
DCV cargos CPE, SgIII and BDNF, but did affect their basal
and KCl-stimulated secretion. Interestingly, basal release of the
SV transmitter glutamate was also impaired by Aβ, while its
evoked discharge was largely preserved. Because Aβ incubations
reduce spontaneous neuronal activity of recurrent networks
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in primary cultures (Rönicke et al., 2011; Lee et al., 2013;
Zurita et al., 2013), it is possible that the intrinsic activity-
driven exocytosis of both SVs and DCVs decreases as Aβ lowers
activation rates. In contrast to basal secretion, when release
was forced by K+-induced depolarization, Aβ selectively impairs
secretion of cargos from DCVs but not from SVs. Although the
cell type source of secreted cargos cannot be addressed in intact
neuro-glial circuitries, alterations in CPE and SgIII release in
treated acute slices from adult brains further substantiate the
notion that Aβ impairs peptidergic secretion in cortical cells.
The present conclusion is supported by previous studies showing
secretion failures in exogenous (ANP.emd) and endogenous
(cystatin C and thrombospondin 1) vesicular cargos in cultured
astrocytes and neurons expressing presenilins carryingmutations
linked to familial Alzheimer disease and incubated with Aβ
(Ghidoni et al., 2007; Rama Rao et al., 2013; Stenovec et al.,
2016).
Because Aβ can induce dysfunctions in different factors and
stages involved in the secretory pathway, how amyloidogenic
peptides affect neural vesicular secretion is uncertain. Aβ
could alter peptidergic secretion influencing vesicular biogenesis,
trafficking and exocytosis. It has been shown that soluble Aβ
forms induce key changes which could compromise the integrity
of the secretory pathway at early stages, such as endoplasmic
reticulum stress, Golgi fragmentation and autophagy (Alberdi
et al., 2013; Joshi et al., 2014; Son et al., 2015). Moreover, Aβ
can also impair transport, docking and discharge of secretory
vesicles. Recent evidence has shown that Aβ disrupts regulated
exocytosis through its direct interaction with SNARE proteins
(Russell et al., 2012; Yang et al., 2015). However, given
that DCVs and SVs share the basic SNARE machinery for
Ca2+-evoked secretion (Gondré-Lewis et al., 2012), the Aβ-
induced impairment in DCV cargo release fromKCl-depolarized
neurons and not for glutamate makes a major contribution
of SNAREs unlikely. On the contrary, a failure of vesicular
trafficking could underlie the secretion changes reported here.
A large body of evidence indicates that defects in microtubule-
mediated transport contribute to the initiation or progression
of neurodegenerative diseases, including AD (Encalada and
Goldstein, 2014; Llorens-Martín et al., 2014). Specifically, soluble
Aβ species impair dendritic and axonal BDNF transport in
cultured neurons (Decker et al., 2010; Gan and Silverman,
2015). Moreover, spontaneous and Ca2+-dependent mobility
of ANP.emd-containing vesicles was diminished in astrocytes
expressing mutated presenilin 1 (Stenovec et al., 2016). Although
a dysregulation of Ca2+ homeostasis and mitochondrial function
could also participate in secretion failure (Ferreira et al.,
2015; Viola and Klein, 2015; De Strooper and Karran, 2016),
we propose that impaired trafficking exerts a central role in
the Aβ-mediated secretion alterations showed in this study.
Furthermore, the aberrant accumulation of granin family
members and CPE detected in dystrophic neurites and neuronal
and astrocyte somata in the cerebral cortex of AD patients
and amyloid-forming transgenic mice strongly supports an Aβ-
induced impairment of vesicular transport and secretion in
the peptidergic transmission (Willis et al., 2011; Plá et al.,
2013). Lastly, which Aβ species are affecting neural peptidergic
secretion is an intricate issue. In our Aβ preparation we virtually
detected aggregates under 200 kDa. However, the array of
different forms and the complex equilibrium among them at
physiological conditions over time make difficult to ascertain
the specific identity of the Aβ assemblies involved in peptidergic
secretion failure (Jan et al., 2011; Moreth et al., 2013; Yang et al.,
2017).
Pathophysiologic Implication of Impaired
Peptidergic Transmission in AD
Due to critical functions of CPE, SgIII and BDNF together with
their wide distribution in the cerebral cortex, it is expected that
the Aβ-induced release impairment showed here is involved in
the AD pathophysiology. It has been shown that CPE and SgIII
sort granins, proneuropeptides, prohormones and pro-BDNF
to DCVs (Cool et al., 1997; Hosaka et al., 2005; Lou et al.,
2005). Therefore, it is likely that proteins belonging to the
regulated secretory pathway, at least those interacting with
CPE and SgIII, are aberrantly co-secreted in the presence of
Aβ. In addition, a dysregulated secretion could disturb the
new extracellular functions attributed to CPE (alternatively
named neurotrophic factor-alpha 1, NF-α1; Cheng et al., 2014).
Moreover, the association of an uncovered CPE/NF-α1 gene
mutation with AD comorbidity further connects CPE with this
neurodegenerative disease (Cheng et al., 2016). Because BDNF
has powerful and recognized effects on synaptic transmission,
plasticity and neuronal survival and is strongly linked with
AD, independently of transcriptional defects, the impact of an
impaired release on neural network functions is anticipated
(Adachi et al., 2014).
Beyond secretion failures for CPE, SgIII and BDNF and
based on a common vesicular trafficking impairment, we
suggest a more general effect of Aβ on both neuronal and
astroglial peptidergic secretion. Because a rise in of soluble Aβ
concentrations in early phases of AD is linked with synaptic
dysfunction and network disorganization, it is conceivable that
alteration of peptidergic transmission, which controls circuitry
function and homeostasis, is involved in AD progression.
It is worth noting that improving levels of DCV cargos
(i.e., BDNF and somatostatin) partially recover AD-altered
networks, preventing cognitive deficits and favoring Aβ clearance
(Saito et al., 2005; Nagahara et al., 2009; Zhang et al., 2015).
Moreover, the aberrant secretion and intracellular accumulation
of CPE and SgIII observed in Aβ-treated and AD mouse and
human brains (Plá et al., 2013) are in line with the low levels
found in the CSF of AD patients by quantitative proteomics
(Fagan and Perrin, 2012). Taking into account the importance
of CSF biomarkers for clinical practice and trial design (Lleó
et al., 2015), CSF changes based on peptidergic secretion failures
could reflect synaptic dysfunction and serve as complementary
diagnostic biomarkers of AD at early stages.
In summary, this study demonstrates that neuronal and
astrocyte secretion of endogenous DCV proteins is impaired by
Aβ in vitro and in situ. Additionally, Aβ-induced dysregulated
peptidergic transmission could play an important role in the
pathogenesis of AD and DCV cargos are possible candidates as
CSF biomarkers.
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